Indefinite Delivery Contract 75D30123D16729
Award Date
7/1/23
Last Date to Order
6/30/24
Federal Agency
CDC Pittsburgh
Awardee
Merck Sharp & Dohme LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts to Merck Sharp & Dohme LLC for adult vaccines. The contracts have a potential value of $83,485,760 and a period of performance from July 1, 2021 to June 30, 2022. Merck will provide 13 standard adult vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus/diphtheria toxoids, herpes zoster, measles/mumps/rubella, meningococcal conjugate, human papillomavirus, and...
The Centers for Disease Control and Prevention (CDC) has awarded a multiple-award Indefinite Delivery Contract (IDC) valued up to $69,520,654.32 to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of various adult vaccines. The contract has a period of performance from July 1, 2024 to June 30, 2025 and does not involve any set-aside designations. The IDC requires Merck, as a pharmaceutical manufacturer, to provide a wide range of adult vaccines including Hepatitis A,...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts valued at up to $25,350,000 to supply adult vaccines for the period of July 1, 2023 through June 30, 2024. The prime contractor is VBI Vaccines (Delaware) Inc. The contracts aim to procure minimum and maximum quantities of 12 adult vaccines, including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles, mumps and rubella,...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts hold a potential value of $102.6 million and require the awarded vendors to provide 13 vaccines to support immunization programs administered by state and local health authorities pursuant to Section 317(j) of the Public Health Service Act. Vaccines include hepatitis A and B, pneumococcal, tetanus/diphtheria, herpes...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract to Bavarian Nordic, Inc. for the procurement of various adult vaccines. The $99,015,000 multiple-award contract has a period of performance from July 1, 2024 to June 30, 2025. The contract does not utilize any set-asides. The solicitation seeks the purchase of vaccines for Hepatitis A, Hepatitis B, Hepatitis...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services, a civilian agency, to Merck Sharp & Dohme Corp. The contract, which has a ceiling value of $129,202,465.56, is for the delivery of adult vaccines under the 2010-2011 Adult Vaccine Contract program. The contract has a period of performance from July 1, 2010 to June 30, 2011 and was not set aside for any specific socioeconomic category. It is a multiple award...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery Contract (IDC) to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of up to 23 standard pediatric vaccines. The $3.301 billion contract will run from April 1, 2022 through March 31, 2023, supporting the CDC's Immunization Awardees and the Vaccines for Children program under Section 317(j) of the Public Health Service Act. The vaccines being procured include a wide range such as DTaP, Hep...
The Centers for Disease Control and Prevention (CDC) has awarded Pfizer Inc. an Indefinite Delivery Contract (IDC) for the supply of various adult vaccines to support immunization programs under Section 317(j) of the Public Health Service Act. The $103,060,230.33 contract, which runs from July 1, 2023 to June 30, 2024, covers a range of vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles-mumps-rubella, meningococcal...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, valued at up to $56,203,651.08, to supply various adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The vaccines to be delivered include hepatitis A, hepatitis B, hepatitis A & B combination, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, tetanus, reduced diphtheria toxoid...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Merck Sharp & Dohme LLC, doing business as Merck, for the purchase of 20 standard pediatric vaccines. The contract supports the CDC's Vaccines for Children program and adult vaccination initiatives under Section 317(j) of the Public Health Service Act. This multiple award IDC has a total ceiling value of $2,565,312,500 and a period of performance of 12 months from the award date...